Market revenue in 2024 | USD 4,115.3 million |
Market revenue in 2030 | USD 8,730.6 million |
Growth rate | 13.6% (CAGR from 2025 to 2030) |
Largest segment | Circulating cell free dna (ccfdna) |
Fastest growing segment | Circulating Cell Free RNA (ccfRNA) / miRNA |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA |
Key market players worldwide | Qiagen NV, Charles River Laboratories International Inc, Roche Holding AG ADR, Thermo Fisher Scientific Inc, Eurofins Scientific SE, PerkinElmer, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Merck KGaA, Siemens Healthineers AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rare biomarkers specimen collection and stabilization market will help companies and investors design strategic landscapes.
Circulating cell free dna (ccfdna) was the largest segment with a revenue share of 39.81% in 2024. Horizon Databook has segmented the Germany rare biomarkers specimen collection and stabilization market based on circulating cell free dna (ccfdna), circulating tumor cells (ctcs), exosomes/extracellular vesicles, circulating cell free rna (ccfrna) / mirna covering the revenue growth of each sub-segment from 2018 to 2030.
Researchers at the German Cancer Research Center are engaged in deciphering the role of exosomes in cancer physiology and facilitate the development of novel therapies for cancer management. Increase in number of research studies in this space is one of the key driving forces of this market.
Furthermore, collaborations between research institutes to accelerate the adoption of novel cancer diagnostic tools are propelling the use of products offered in this market. For instance, in September 2016.
New research findings on the potential of liquid biopsy in monitoring patients with lung cancer were published as a result of a collaboration between the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ), and the Thoraxklinik Heidelberg.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany rare biomarkers specimen collection and stabilization market , including forecasts for subscribers. This country databook contains high-level insights into Germany rare biomarkers specimen collection and stabilization market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account